ZymoGenetics Names Heather Franklin Senior Vice President of Business Development

SEATTLE--(Business Wire)--
ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that Heather L.
Franklin has been named Senior Vice President, Business Development
and will serve as a member of the company's Executive Management
Committee.

"Heather's promotion reflects her significant contributions toward
business development transactions and strategic alliance management,
including the RECOTHROM partnership with Bayer and the Merck Serono
alliance," said Bruce L.A. Carter, Ph.D., Chief Executive Officer of
ZymoGenetics. "Her superior negotiating skills and ability to create
deals with advantageous terms for the company will be a tremendous
asset in the future."

Prior to her appointment as Senior Vice President, Business
Development, Ms. Franklin was Vice President, Business Development
from January 2005 to June 2008 at ZymoGenetics. Prior to that, she
served as Senior Director, Strategic Alliance Management from July
2003 to January 2005 and Director, Strategic Alliance Management from
January 2002 to July 2003. In these roles she was instrumental in
negotiating and managing major partnerships with Novo Nordisk, Merck
Serono and Bayer. Ms. Franklin joined ZymoGenetics in January, 2001 as
Director, Research Project Management to establish a research project
management system after holding roles of increasing responsibility in
clinical and research project management at Amgen and Targeted
Genetics from 1994 to 2001. She started her career in research roles
at Seattle Biomedical Research Institute and Targeted Genetics. Ms.
Franklin received a B.S. from the University of North Carolina, Chapel
Hill, M.S. from the University of Washington and an M.B.A from the
Wharton School of the University of Pennsylvania.

About ZymoGenetics

ZymoGenetics creates novel protein drugs with the potential to
significantly help patients fight their diseases. The Company is
developing a diverse pipeline of product candidates that are moving
into and through clinical development. These candidates span a wide
array of clinical opportunities that include bleeding, autoimmune and
viral diseases and cancer. ZymoGenetics intends to commercialize these
product candidates through internal development, collaborations with
partners, and out-licensing of patents from its extensive patent
portfolio. For further information, visit www.zymogenetics.com.

This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on the current intent and
expectations of the management of ZymoGenetics. These statements are
not guarantees of future performance and involve risks and
uncertainties that are difficult to predict. ZymoGenetics' actual
results and the timing and outcome of events may differ materially
from those expressed in or implied by the forward-looking statements
because of risks associated with our unproven product sales and
marketing abilities, discovery strategy, preclinical and clinical
development, strategic partnering, regulatory oversight, intellectual
property claims and litigation and other risks detailed in the
company's public filings with the Securities and Exchange Commission,
including the company's Annual Report on Form 10-K for the year ended
December 31, 2007. Except as required by law, ZymoGenetics undertakes
no obligation to update any forward-looking or other statements in
this press release, whether as a result of new information, future
events or otherwise.

ZymoGenetics, Inc.
Susan W. Specht, MBA, 206-442-6592
Director, Corporate Communications
or
Michael Fitzpatrick, 206-442-6702
Associate Director, Corporate Communications

Copyright Business Wire 2008